Abstract
In this multicenter randomized trial, the efficacy of combination chemotherapy using 5-fluorouracil, doxorubicin and mitomycin C (arm A) was compared with that of 5-fluorouracil alone (arm B) in 81 patients with nonresectable carcinomas of the pancreas or biliary tract. There were no significant differences between treatment arms regarding the median time to progressive disease, median survival time, palliative effects or toxicities. It was concluded that combination chemotherapy is feasible but cannot be recommended.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biliary Tract Neoplasms / drug therapy*
-
Biliary Tract Neoplasms / mortality
-
Confidence Intervals
-
Doxorubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage*
-
Humans
-
Male
-
Middle Aged
-
Mitomycin / administration & dosage
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / mortality
-
Survival Rate
Substances
-
Mitomycin
-
Doxorubicin
-
Fluorouracil